Literature DB >> 12925366

Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy.

Avinash Prasad1, Ruben I Kuzniecky, Robert C Knowlton, Tim E Welty, Roy C Martin, M Mendez, Raymond E Faught.   

Abstract

BACKGROUND: In the face of availability of newer antiepileptic drugs (AEDs) such as lamotrigine and topiramate, there is need to reassess the role of older AEDs in the treatment of juvenile myoclonic epilepsy (JME).
OBJECTIVES: To explore whether lamotrigine and topiramate monotherapy or polytherapy can be effective options in the treatment of JME, and to determine whether older AEDs, such as phenytoin and carbamazepine, have a role in the treatment of JME.
DESIGN: A retrospective cohort study.
SETTING: A large academic teaching hospital. PATIENTS: Seventy-two consecutive JME patients treated with valproic acid, lamotrigine, topiramate, phenytoin, or carbamazepine between April 1, 1991, and March 31, 2001.
METHODS: We compared the efficacy of valproic acid, lamotrigine, and topiramate monotherapy or polytherapy in the control of different seizure types of JME, and compared their efficacy and tolerability with the efficacy and tolerability of phenytoin and carbamazepine.
RESULTS: Seizure outcome did not differ when patients receiving valproic acid monotherapy (n = 36) were compared with those receiving lamotrigine monotherapy (n = 14), and when patients receiving valproic acid polytherapy (n = 22) were compared with those receiving lamotrigine polytherapy (n = 21) or topiramate polytherapy (n = 15) (P>.05 for all). The combined data of myoclonic seizure control by all 3 AEDs were poorer when compared with the combined data of generalized tonic-clonic seizure control by all 3 AEDs (P =.03), but not when compared with the combined data of absence seizure control by all 3 AEDs (P =.43). Valproic acid, lamotrigine, and topiramate, when compared with phenytoin or carbamazepine, demonstrated significantly better control of myoclonic seizures (P<.01 for all), but not of generalized tonic-clonic seizures (P>.11 for all).
CONCLUSIONS: Lamotrigine and topiramate are effective alternative options to valproic acid in the treatment of JME. Lamotrigine is an effective option as monotherapy and polytherapy. Topiramate is an effective option as polytherapy, but more data are needed to determine if it is an effective option as monotherapy. More effective therapy is needed to improve myoclonic seizure control. Older AEDs, such as phenytoin and carbamazepine, may not be indicated in JME patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12925366     DOI: 10.1001/archneur.60.8.1100

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Improvement of cervico-trunco-brachial segmental dystonia with topiramate.

Authors:  Spiridon Papapetropoulos; Carlos Singer
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

2.  Levetiracetam efficacy in idiopathic generalized epilepsy: long suspected and now confirmed in randomized clinical trials.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2008 Jan-Feb       Impact factor: 7.500

3.  Juvenile myoclonic epilepsy: more trials are needed to guide therapy.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2009 Jan-Feb       Impact factor: 7.500

4.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

5.  Cortical and subcortical contributions to absence seizure onset examined with EEG/fMRI.

Authors:  Jerzy P Szaflarski; Mark DiFrancesco; Thomas Hirschauer; Christi Banks; Michael D Privitera; Jean Gotman; Scott K Holland
Journal:  Epilepsy Behav       Date:  2010-06-26       Impact factor: 2.937

Review 6.  Juvenile myoclonic epilepsy: epidemiology, pathophysiology, and management.

Authors:  Timothy E Welty
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Seizure control in patients with idiopathic generalized epilepsies: EEG determinants of medication response.

Authors:  Jerzy P Szaflarski; Christopher J Lindsell; Tarek Zakaria; Christi Banks; Michael D Privitera
Journal:  Epilepsy Behav       Date:  2010-03-12       Impact factor: 2.937

8.  Update on the newer antiepileptic drugs in child neurology: advances in treatment of pediatric epilepsy.

Authors:  Mazin Abdul; James J Riviello
Journal:  Curr Treat Options Neurol       Date:  2007-11       Impact factor: 3.598

9.  Idiopathic Generalized Epilepsy.

Authors:  Joseph E. Sullivan; Dennis J. Dlugos
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

10.  Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy.

Authors:  Stéphane Auvin
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.